Shattuck Labs (STTK) Projected to Announce Earnings on Thursday

Shattuck Labs (NASDAQ:STTK) is projected to post its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect Shattuck Labs to announce earnings of ($0.1241) per share for the quarter. Parties can check the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Monday, August 10, 2026 at 12:30 PM ET.

Shattuck Labs (NASDAQ:STTK) last announced its earnings results on Thursday, May 7th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.01. During the same quarter last year, the firm posted ($0.27) EPS. On average, analysts expect Shattuck Labs to post $-0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Shattuck Labs Stock Down 6.9%

Shares of STTK stock opened at $7.37 on Thursday. The company has a market capitalization of $565.13 million, a P/E ratio of -11.70 and a beta of 1.08. Shattuck Labs has a 12-month low of $0.71 and a 12-month high of $8.33. The firm has a 50-day moving average price of $6.14 and a 200 day moving average price of $5.82.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. Jefferies Financial Group raised shares of Shattuck Labs to an “outperform” rating and set a $7.00 price objective for the company in a report on Friday, June 5th. JPMorgan Chase & Co. started coverage on Shattuck Labs in a report on Friday, July 24th. They issued an “overweight” rating and a $10.00 target price on the stock. Wall Street Zen upgraded Shattuck Labs from a “hold” rating to a “buy” rating in a research report on Saturday, June 13th. Citigroup raised Shattuck Labs from a “neutral” rating to a “buy” rating and set a $7.00 price target for the company in a report on Friday, June 5th. Finally, Cantor Fitzgerald began coverage on Shattuck Labs in a research report on Monday, April 27th. They issued an “overweight” rating for the company. Ten analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Shattuck Labs has an average rating of “Moderate Buy” and an average price target of $12.62.

Insiders Place Their Bets

In related news, insider Arundathy N. Pandite sold 30,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $6.61, for a total value of $198,300.00. Following the completion of the transaction, the insider owned 166,219 shares in the company, valued at $1,098,707.59. The trade was a 15.29% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Clay B. Siegall acquired 62,500 shares of Shattuck Labs stock in a transaction on Tuesday, June 9th. The shares were purchased at an average cost of $4.00 per share, for a total transaction of $250,000.00. Following the acquisition, the director owned 318,608 shares in the company, valued at approximately $1,274,432. This represents a 24.40% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders sold 85,907 shares of company stock valued at $591,850. Insiders own 8.79% of the company’s stock.

Hedge Funds Weigh In On Shattuck Labs

Large investors have recently made changes to their positions in the company. AQR Capital Management LLC increased its position in Shattuck Labs by 265.4% in the first quarter. AQR Capital Management LLC now owns 43,169 shares of the company’s stock worth $41,000 after purchasing an additional 31,355 shares during the period. Jacobs Levy Equity Management Inc. acquired a new stake in shares of Shattuck Labs during the 1st quarter worth approximately $81,000. Acadian Asset Management LLC raised its stake in shares of Shattuck Labs by 27.6% during the first quarter. Acadian Asset Management LLC now owns 257,345 shares of the company’s stock worth $243,000 after buying an additional 55,687 shares during the last quarter. Qube Research & Technologies Ltd acquired a new position in Shattuck Labs in the second quarter valued at approximately $44,000. Finally, Jane Street Group LLC boosted its stake in Shattuck Labs by 2,510.8% in the second quarter. Jane Street Group LLC now owns 289,671 shares of the company’s stock valued at $229,000 after acquiring an additional 278,576 shares during the last quarter. Institutional investors and hedge funds own 58.74% of the company’s stock.

About Shattuck Labs

Shattuck Labs, Inc (NASDAQ: STTK) is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.